Introduction
The oncogenes of adenovirus, E1A and E1B, play an essential role in establishing a productive virus infection in human cells, and are both necessary and sucient for transformation of primary rodent epithelial cells (White, 1995 (White, , 1998 . The products of the E1A and E1B genes also modulate the interaction between the infected cell and the immune system of the human or rodent host (Wold et al., 1999) . E1A stimulates entry into S phase to create the appropriate environment for the replication of viral DNA in productively infected human cells. This same growth deregulatory function of E1A is also essential to the transformation of primary rodent cells. E1A accomplishes cell cycle deregulation by binding to and perturbing the normal function of key negative regulators of cell growth, including the retinoblastoma protein (Rb), and the transcriptional coactivator p300. Ironically, these very activities of E1A that are required for productive virus infection and oncogenic transformation also stimulate programmed cell death (apoptosis) (White, 1995 (White, , 1998 . Apoptosis is the cellular defensive response to gross perturbation in cell growth regulation induced by E1A during virus infection and transformation. E1A expression in productively infected cells also decreases the threshold of killing by death signaling cytokines, such as tumor necrosis factor-alpha (TNF-a), which facilitates death of infected cells. Neither of these events is favorable for virus production. In transformation, the induction of apoptosis by E1A nearly abrogates the oncogenic activity of E1A, and necessitates that E1A be coexpressed with an inhibitor of apoptosis for transformation to occur. All of these proapoptotic activities are counteracted by expression of E1B, which sustains productive infection and transformation. E1B encodes two proteins, E1B 55K and E1B 19K, which function in all or in part by inhibiting apoptosis (White, 1995 (White, , 1998 . E1B 55K binds and inhibits the function of the p53 tumor suppressor protein, which has well-known roles in inhibiting cell cycle progression and stimulating apoptosis (Levine, 1997) . E1B 19K is an anti-apoptotic adenoviral Bcl-2 homologue. Bcl-2 is the prototypical member of a family of proteins that regulate apoptosis . A gain-offunction in an anti-apoptotic Bcl-2 family member can promote cell survival and oncogenesis, whereas proapoptotic Bcl-2 family members are required for mediating apoptosis in development, and likely by tumor suppressor proteins in emerging cancer cells. The homology between E1B 19K and Bcl-2 includes direct sequence homology, functional interchangeability as apoptosis inhibitors, and interaction with some of the same intracellular proteins, implying a related biochemical function. E1B 19K blocks apoptosis induced by E1A in productive infection, by signaling from death ligands such as TNF-a, Fas ligand (FasL), and TRAIL emanating from an immune response, and by p53 in the transformation setting. Over the years we have been unraveling the molecular mechanisms by which E1A and E1B regulate cell proliferation and apoptosis in productive infection, in death receptor signaling, and by p53 in transformation. Much of what we have learned has direct parallels to the mechanisms by which normal human cells are converted to cancer cells. By de®ning these mechanisms we hope to provide novel avenues for therapeutic intervention in cancer treatment, and to have a better understanding of virushost interactions.
E1A sensitizes cells to apoptosis induced by TNF-a by promoting the degradation of c-FLIP S in the proteasome E1A expression during virus infection and in stable cell lines sensitizes cells to killing by death receptor ligands TNF-a (Chen et al., 1987; Cook et al., 1989; DuerksenHughes et al., 1989) , FasL, and TRAIL (Routes et al., 2000) . Increased sensitivity of infected cells to TNF-a would generally be detrimental to virus infection. Expression of the anti-apoptotic viral genes E1B 19K and E3, however, confers resistance to TNF-a and ameliorates any deleterious eect brought about by E1A sensitizing infected cells to killing by death receptor signaling (Wold et al., 1999) . Death receptors and their ligands signal cell death by apoptosis and E1A is thought to relieve a constitutive survival mechanism to sensitize cells to this apoptosis. Identi®cation of this sensitization mechanism has the potential to reveal a means to increase the sensitivity of cancer cells to apoptosis.
The major aspects of the pathway of death signaling by TNF-a, FasL, and TRAIL have been established (Figure 1 ) (Cleveland and Ihle, 1995; Krammer, 2000; Nagata, 1997) . What they all share in common is the recruitment of adaptor proteins including FADD, and the cysteine protease procaspase-8, to the death receptor signaling complex (DISC). Procaspase-8 then undergoes autocatalytic processing to caspase-8 by internal cleavage at multiple sites that remove the prodomain and liberate p17 and p10 subunits to form a heterotetramer, which is the active caspase. Caspase-8 then cleaves the Bcl-2 family member Bid to tBid (Li et al., 1998; Luo et al., 1998) , which binds other Bcl-2 family members Bax and Bak to promote the release of mitochondrial components including cytochrome c and Smac/DIABLO . Cytochrome c is an activator of caspase-9 (Li et al., 1997) and Smac/DIABLO is an inhibitor of a family of caspase-9 inhibitors, the inhibitors of apoptosis (IAPs) (Du et al., 2000; Verhagen et al., 2000) . Thus cytochrome c and Smac/ DIABLO collaborate to promote the activation of caspase-9, which in turn, cleaves and activates caspase-3 in the caspase activation cascade in apoptotic cell death (Goyal, 2001) . Caspase-3 cleaves many cellular substrates such as other caspases, and the inhibitor of the apoptotic nuclease (ICAD/DFF45) that activates the apoptotic nuclease (CAD/DFF40) to induce DNA fragmentation. This collective cleavage of cellular substrates leads to the ordered destruction of the cell (Cryns and Yuan, 1998) .
Implementation of apoptosis by death receptors and their ligands also requires coordinate disabling of survival signals, either activated by the death receptors themselves, or those which are an intrinsic property of the cell type (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996) . TNF-a for example, activates not only caspase-8 but also NF-kB, which upregulates the transcription of a number of pro-survival Bcl-2 family members and IAPs (Barkett and Gilmore, 1999; Pahl, 1999) . IAPs can be recruited to the DISC of the TNF receptor 1 through interaction with adaptor proteins, the TRAFs, although overexpression of a single IAP is usually not sucient to block death signaling by TNF-a. Thus, apoptosis induction by TNF-a usually requires inhibition of protein synthesis. Still other cells constitutively express inhibitors of death receptor signaling pathways by virtue of their cell type or dierentiation state. E1A expression has the unusual property that it can take the place of protein synthesis inhibitors, and renders cells sensitive to apoptosis induction by TNF-a alone. There has been considerable interest in the mechanism by which E1A sensitizes cells to apoptosis induced by TNF-a and other death receptor ligands as a paradigm for increasing the sensitivity of resistant tumor cells to apoptosis.
A clue to the possible mechanism by which E1A sensitizes cells to TNF-a emerged when caspase-8 activation by TNF-a was examined in E1A-expressing adenovirus infected cells. Treatment of cells with TNFa alone is normally insucient to activate caspase-8 and induce apoptosis, whereas E1A expression during virus infection permitted TNF-a to activate caspase-8 (Perez and White, 2000) . This observation indicated that E1A was sensitizing cells to TNF-a by facilitating TNF-a-dependent activation of caspase-8 at the DISC, and not by regulating signaling events downstream. Mechanisms by which E1A would inhibit NF-kBdependent induction of pro-survival target genes, whose products function to block apoptosis downstream of the DISC, can thereby be excluded. Since most of the components of the DISC are known, some of which are direct inhibitors of caspase-8 activation by TNF-a such as¯ice inhibitory proteins (c-FLIP S ) (Hu et al., 1997b; Irmler et al., 1997) and IAP-1 and -2 (Chu et al., 1997; Wang et al., 1998) , we examined whether E1A aected c-FLIP S or IAPs.
Multiple isoforms of c-FLIP are produced from the c-FLIP gene, and all are essentially dominant negative caspases. The long form of c-FLIP (c-FLIP L ) is highly homologous to caspase-8 and other large pro-domain containing caspases except that FLIP L is an inactive cysteine protease (Tschopp et al., 1998) . The short form of c-FLIP (c-FLIP S ) encodes only the caspase pro-domain utilized for caspase interaction. Both long and short forms of c-FLIP competitively inhibit caspase-8 activation at the DISC, but it is c-FLIP S that functions to block apoptosis during T cell activation (Kirchho et al., 2000) . IAPs are E3 Figure 1 Regulation of DISC function by E1A and the proteasome Oncogene Apoptosis regulation by E1A and E1B E White ubiquitin ligases that implement ubiquitination and degradation of both themselves, and perhaps other apoptosis regulators (Huang et al., 2000; Yang et al., 2000) . Thus, activation of caspase-8 by death receptors can be interfered with potentially by either blocking caspase-8 activation through direct antagonism (c-FLIP mechanism) or by eliminating apoptosis promoting eector proteins (IAP mechanism). We therefore examined whether E1A could act as either a c-FLIP or IAP inhibitor to promote TNF-a-dependent caspase-8 activation.
TNF-a induces the accumulation of c-FLIP S but not c-FLIP L , and E1A expression during virus infection dramatically inhibits this TNF-a-dependent induction of c-FLIP S (Figure 1 ) (Perez and White, submitted) . The inhibition of TNF-a-dependent c-FLIP S protein accumulation requires E1A expression by adenovirus, indicating that c-FLIP S levels are being solely modulated by E1A (Perez and White, submitted) . Cells derived from c-FLIP null mouse embryos display increased sensitivity to TNF-a (Yeh et al., 2000) , consistent with the elimination of c-FLIP S by E1A as the cause of TNF-a sensitization. Indeed, c-FLIP L or c-FLIP S overexpression is sucient to confer resistance to TNF-a plus cycloheximide, and cycloheximide blocks the induction of c-FLIP S accumulation by TNF-a (Kreuz et al., 2001; Perez and White, submitted) . Apparently E1A may mimic the mechanism used by protein synthesis inhibitors to promote sensitivity to TNF-a.
E1A inhibits c-FLIP S accumulation by stimulating c-FLIP S degradation in proteasomes. This was clearly demonstrated as c-FLIP S protein levels could be restored in E1A expressing cells by the presence of proteasome inhibitors (Perez and White, submitted) . IAP-2, but not IAP-1 levels are also down regulated by E1A, suggesting that IAP-2 may also contribute to the E1A sensitization mechanism. As IAP-2 is a ubiquitin ligase, it may be responsible for targeting the degradation of c-FLIP S . Moreover, expression of a viral version of c-FLIP, v-FLIP MC159 from mulluscum contagiosum virus (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) , rescued E1A sensitization and prevented TNF-a alone from activating caspase-8 and inducing apoptosis during adenovirus infection (Perez and White, submitted) . This indicates that the proteasomedependent degradation of c-FLIP S , which may be regulated by IAP-2, is responsible for E1A expressing, virus infected cells being sensitized to apoptosis induction by TNF-a, and other death receptor ligands.
The ability of E1A to sensitize cells to apoptosis by TNF-a Shisler et al., 1996) , to promote TNF-a alone-dependent activation of caspase-8, and to cause the proteasome-dependent destruction of c-FLIP S and IAP-2, cosegregated with the Rb and p300 binding activities of E1A (Figure 1 ) (Perez and White, submitted) . The Rb and p300 binding activities of E1A are responsible for cell cycle deregulation and the stimulation of S phase progression and are thereby required for oncogenic transformation. This perturbation of the growth suppressive function of Rb and p300 by E1A alters their normal regulation of cellular gene transcription, suggesting that activation of proteasome-dependent c-FLIP S degradation may result from changes in gene expression.
Tumor cells can evolve to have altered sensitivity to apoptosis. For example, oncogenic events such as cmyc deregulation, also sensitizes tumor cells to TNF-a and other apoptotic signals (Klefstron et al., 1994) . These alterations can be favorable to clinical treatment in that tumor cells can be preferentially killed in comparison to normal cells. Alternatively, activation of a survival mechanism can reduce the apoptotic propensity of tumor cells, and may even be selected for in vivo. Tumor cells can acquire resistance to killing by intrinsic mechanisms (p53, for example), by the immune system, or by therapeutic intervention (chemotherapy and radiation, for example). Restoration of the apoptotic propensity to resistant tumor cells should be a laudable goal, and the ability of E1A to target the destruction of c-FLIP S may provide a novel means to lower the threshold for triggering apoptosis. Some tumors have been reported to express high levels of c-FLIP (Irmler et al., 1997; Thome et al., 1997) and there is evidence that this plays a role in evading immune surveillance and in disease progression (Djerbi et al., 1999; Medema et al., 1999) . Knowing that c-FLIP s and IAPs can be speci®cally targeted for degradation in the proteasome, and that this can restore the ability of death receptors and their ligands to induce cell death, provides a novel mechanism to manipulate the eectiveness of cancer treatments.
DNA virus transforming proteins have a long history of manipulating proteasome-mediated degradation of cellular proteins as a means to implement their function. Human papilloma virus (HPV) E6 in conjunction with cellular E6AP, promotes the ubiquitination and proteasome-dependent degradation of p53 (Schener et al., 1993) . Adenovirus E1B 55K, in conjunction with E4orf6, also targets p53 for degradation in the proteasome (Querido et al., 1997a; Steegenga et al., 1998) . E1A, perhaps via the E3 ligase IAP-2, apparently triggers c-FLIP S degradation by a similar mechanism. Unlike the targeted destruction of p53 by HPV E6 and adenovirus E1B 55K-E4orf6, the destruction of c-FLIP S by E1A likely results indirectly from the response of the cell to the deregulation of cell growth induced by E1A. The functional consequences of sensitizing cells to apoptosis by E1A eliminating c-FLIP S are not a problem for the virus as long as E1B 19K is expressed to prevent apoptosis by death receptor signaling pathways. Thus E1B 19K is the adenovirus antidote to the deleterious side eects of E1A expression during virus infection and transformation.
E1B 19K blocks death receptor mediated apoptosis by preventing mitochondrial pore formation by Bax and Bak
The E1B 19K protein functions as an apoptosis inhibitor in transformation by blocking p53-dependent apoptosis (Debbas and White, 1993) , and in virus infection by blocking both E1A-induced and p53-independent apoptosis White et al., 1991) , and apoptosis mediated by death receptor signaling via TNFa/TNF receptors, FasL/Fas, and TRAIL/DR4/5 Hashimoto et al., 1991; White et al., 1992; Wold et al., 1999) . TNF-a treatment causes rapid and ecient degradation of host cell and viral DNA, and cell death by apoptosis, which is completely prevented by E1B 19K expression during virus infection . This inhibition of apoptosis by tumoricidal cytokines, particularly TNF-a, is an important mechanism utilized by adenovirus and many other viruses to avoid immune surveillance by the host. Failure to inhibit TNF-a-mediated killing of infected cells typically results in a massive in¯ammatory response, which is detrimental to both the infected cell and to the host (Berensci et al., 1994; Ginsberg and Prince, 1994; Sparer et al., 1996) . We have determined the mechanism by which the E1B 19K protein blocks apoptosis by TNF-a by examining the death signaling pathway in infected cells and de®ning the point where death signaling is blocked. This mechanism is remarkably similar to the means by which p53-and E1A-mediated apoptosis are inhibited, and involves direct binding between the E1B 19K protein and the pro-apoptotic Bax and Bak proteins, thereby inhibiting their propagation of the death signal emanating from mitochondria.
Expression of the E1B 19K protein during wild-type adenovirus infection completely blocks apoptosis induction by TNF-a without aecting the level of cell surface receptors for TNF-a, suggesting that inhibition was taking place at the level of intracellular signaling . E1B 19K can eciently inhibit apoptosis induced by FADD overexpression and activation of endogenous caspase-8, but not by caspase-8 overexpression (Perez and White, 1998 ) that can directly activate caspase-3 (Scadi et al., 1999) . This suggests that inhibition of death signaling is occurring at or between FADD and caspase-3. E1B 19K expression during virus infection does not block caspase-8 activation by TNF receptors, nor does it block caspase-8 from cleaving Bid to tBid (Perez and White, 2000) . The E1B 19K protein apparently interrupts death receptor signaling downstream of caspase-8 activation and Bid cleavage, and surprisingly, cell viability can be sustained even when caspase-8 is active.
The E1B 19K protein binds to both Bax and Bak and inhibits their ability to induce apoptosis (Farrow et al., 1995; Han et al., 1996 Han et al., , 1998 . tBid binds to and activates the pro-apoptotic function of Bax and Bak in mitochondria (Desagher et al., 1999; Eskes et al., 2000; Perez and White, 2000; Wei et al., 2000) . Thus, activation of Bax and Bak by tBid, and potential inhibition by E1B 19K, was examined as a plausible mechanism for regulation of TNF-a-mediated death signaling. In untreated, healthy cells, E1B 19K does not interact with Bax (Perez and White, 2000) . TNF-a treatment induces interaction between tBid and Bax and an interaction between E1B 19K and Bax, but not a ternary complex between tBid, Bax, and E1B 19K. Interestingly, tBid expression induces a conformational change in the amino-terminus of Bax, visualized by exposure of an amino-terminal Bax epitope (Perez and White, 2000) . Taken collectively, this suggests that the generation of tBid by caspase-8 induces tBidBax interaction and a conformational change resulting in exposure of the Bax amino-terminus. With its aminoterminus exposed, Bax can then gain the ability to interact with the E1B 19K protein, and presumably lose the ability to interact with tBid (Figure 2) . tBid would then act by a hit-and-run mechanism to activate Bax. The domain on Bax that is both necessary and sucient for E1B 19K binding is the 28 amino acid Bax BH3 that is near the amino-terminus (Han et al., 1996) . It is possible that the conformational change in the Bax amino-terminus results in the exposure of the E1B 19K binding domain (BH3) on Bax, which permits E1B 19K-Bax interaction (Perez and White, 2000) .
TNF-a treatment also induces a conformational change in the Bax carboxy-terminus, which is revealed by exposure of the BH2 epitope ). The structure of Bax and the other Bcl-2 family members Bcl-x L , Bcl-2, and Bid (Aritomi et al., 1997; Chou et al., 1999; McDonnell et al., 1999; Muchmore et al., 1996; Petros et al., 2001; Sattler et al., 1997) , resembles that of the pore-forming domains of diphtheria toxin and the colicins. These pore-forming toxin domains have two central helices surrounded by amphipathic helices. To generate a membrane pore, the toxin domain undergoes a conformational change, which exposes the two central helices to allow membrane insertion followed by oligomerization, which is necessary for pore formation (Gazit et al., 1998; Gerber and Shai, 2000; Gilbert et al., 1999; Manoj and Aronson, 1999) . Analogously, for Bax to form a pore, conformational changes in both the Bax amino-and carboxy-termini would be necessary to expose the two central helices, and also to liberate the carboxyterminal transmembrane domain. Binding between E1B 19K and Bax occurs following the aminoterminal conformational change in Bax (Perez and White, 2000) , however, exposure of the Bax carboxyterminal epitope is blocked by E1B 19K expression in adenovirus infected, TNF-a treated cells ). This suggests that although E1B 19K-Bax interaction is stimulated by opening up of the Bax amino-terminus, E1B 19K-Bax complex formation may prevent the second conformational change in the Bax carboxy-terminus. E1B 19K expression also blocks the oligomerization of Bax into a 500 kDa complex that would normally occur in response to TNF-a (Figure 2 ) . By analogy with the pore-forming toxin domains, Bax may undergo conformational changes that expose the two central helices and the transmembrane domain to facilitate mitochondrial membrane insertion, oligomerization, and pore formation. E1B 19K may block mitochondrial pore formation by Bax, by binding to Bax, and preventing Bax oligomerization, thereby preventing the propagation of death signals from mitochondria.
Oncogene Apoptosis regulation by E1A and E1B E White
The E1B 19K protein interacts with Bak (Farrow et al., 1995) , the pro-apoptotic activity of which is also activated by tBid-Bak binding . Unlike Bax, the Bak-E1B 19K interaction appears constitutive and is not induced by TNF-a (Sundararajan et al., 2001). Bax-Bak interaction, however, is induced by TNF-a, and E1B 19K expression during virus infection blocks this Bax-Bak binding (Figure 2 ) . Bak may interact with Bax to promote Bax oligomerization, which is consistent with cofractionation of Bak with the 500 kDa Bax complex in TNF-a treated cells ). Indeed, Bax or Bak de®cient baby mouse kidney (BMK) cells are not defective for TNF-a-mediated apoptosis, but those doubly de®cient for Bax and Bak are profoundly resistant (Degenhardt et al., in preparation). E1B 19K expression also prevents Bak as well as Bax oligomerization stimulated by TNF-a . Thus the E1B 19K protein may function at multiple levels to block mitochondrial death signal propagation (Figure 2) . First, by binding to Bak, E1B 19K may prevent Bak oligomerization and pore formation as well as Bak-dependent Bax activation, co-oligomerization and pore formation. Second, by binding to Bax, E1B 19K may prevent not only Bak-dependent Bax activation, but also Bax activation by other means. Third, by binding to Bax, E1B 19K may play a direct role in inhibiting Bax oligomerization.
In addition to the structural homology with poreforming toxin domains, there is biochemical evidence that Bcl-2 family members can act as channels or pores in membranes or lipid bilayers . Biological evidence suggests that Bax and Bak both participate in the release of cytochrome c from mitochondria. Cells de®cient for either Bax or Bak still release cytochrome c and die in response to death stimuli, whereas Bax and Bak doubly de®cient cells are unable to release cytochrome c in response to apoptotic signaling through mitochondria and are resistant to apoptosis (Degenhardt et al., in preparation; Wei et al., 2001) . E1B 19K expression blocks the release of cytochrome c and Smac/DIABLO that would normally occur upon treatment of cells with TNF-a (Perez and White, 2000; . As cytochrome c is an activator of caspase-9 and Smac/DIABLO is an inhibitor of a caspase-9 inhibitor, the block to cytochrome c and Smac/DIABLO release by E1B 19K should prevent caspase-9 activation by TNF-a, and indeed it does (Perez and White, 2000) . Caspase-9-dependent caspase-3 activation is also inhibited by E1B 19K expression, although the cleavage of caspase-3 by caspase-8 is not aected (Perez and White, 2000) . Since E1B 19K acts downstream of caspase-8, inhibition of apoptosis at the level of Bax and Bak at the mitochondria would only interrupt the processing of caspase-3, which is exactly what we observed ( Figure  2 ). The inhibitory eect of E1B 19K at the level of mitochondria is nonetheless sucient to block apoptosis.
The parallels of structural similarities, conformational changes, membrane insertion, oligomerization, and pore formation demonstrated by both the bacterial toxins and pro-apoptotic Bax and Bak, is striking. In addition to pore forming toxins, bacteria also encode immunity proteins, which permit toxin resistance. The mechanism by which E1B 19K functions to inhibit apoptosis by Bax and Bak has parallels with the function of bacterial immunity proteins that inhibit pore formation by bacterial toxins (Sundararajan and Apoptosis regulation by E1A and E1B E White . Immunity proteins can bind to and prevent oligomerization of the toxin pore-forming domains and thereby block pore formation and toxicity (Taylor et al., 2000; Zhang and Cramer, 1993) . In parallel to the function of immunity proteins, the E1B 19K protein binds and prevents Bax and Bak oligomerization ) and the ability of Bax and Bak to act as membrane pores in vivo to release proteins from mitochondria (Perez and White, 2000; . As bacteria are the progenitors of mitochondria, this functional antagonism between pore-forming toxins and their corresponding immunity proteins may be conserved in mammals. Adenovirus may have functionally modeled its anti-apoptotic E1B 19K protein after the immunity proteins to aect blockade of apoptosis in virus-infected cells ).
Regulation of p53-dependent apoptosis by E1A and E1B at the mitochondria during oncogenic transformation E1A is a potent oncogene and transforms primary baby rat kidney (BRK) or baby mouse kidney (BMK) cells when coexpressed with either adenovirus E1B or Haras. Expression of E1A alone in BRK or BMK cells induces cell proliferation in conjunction with apoptosis, causing abortive transformation (Degenhardt et al., in preparation, Rao et al., 1992; White et al., 1992) . Thus to sustain transformation, E1A must be coexpressed with an apoptosis inhibitor, which can come in the form of an anti-apoptotic Bcl-2 family member (E1B 19K or Bcl-2), or a stimulator of survival signaling pathways (Ha-ras) (Lin et al., 1995; Rao et al., 1992; White et al., 1992) . The induction of apoptosis by E1A in transformed BRK cells is p53-dependent (Debbas and White, 1993) . E1A causes p53 accumulation by increasing the half-life of the p53 protein, which is attributed to the Rb and p300 binding activities of E1A (Figure 3 ) Lowe and Ruley, 1993; Querido et al., 1997b) . Inhibition of p300 by E1A can interfere with either direct eects of p300 on p53 stability (Grossman et al., 1998) or p53-dependent transactivation of Mdm-2 (Thomas and White, 1998), which is an E3 ubiquitin ligase that promotes p53 turnover (Haupt et al., 1997; Kubbutat et al., 1997) . Inhibition of Rb by E1A activates E2F (Nevins, 1992) , which promotes expression of the Mdm-2 inhibitor p19 ARF , thus causing p53 stabilization (de Stanchina et al., 1998; Pomerantz et al., 1998; Sherr, 1998) . Either inhibitors of p53 function (dominant-negative p53 mutants or E1B 55K) (Debbas and White, 1993; Rao et al., 1992) , or p53 de®ciency itself (Degenhardt et al., in preparation; Lowe et al., 1994) , blocks this E1A-mediated, p53-dependent apoptosis and allows the ecient transformation of primary cells by E1A alone.
The dependence of E1A-mediated apoptosis on p53 was clearly demonstrated utilizing a temperature sensitive mutant of p53. Transformation of BRK cells with E1A and a temperature sensitive p53 mutant facilitates transformation by E1A when p53 is mutant, but the cells undergo apoptosis rapidly when p53 reverts to the wild-type conformation at the permissive temperature (Debbas and White, 1993) . Finally, the rare transformed foci that emerge from the transformation of BRK cells with E1A alone have mutations in p53 identical to those found in some human tumors (L Goyal and E White, unpublished observations). Thus, p53 responds to E1A by promoting apoptotic cell death, which illustrates the functional interconnection between deregulation of the cell cycle in transformation and the activation of an intrinsic cell suicide pathway by p53 to eliminate these abnormal cells.
p53 is mutated in half of all human tumors and it is a well-characterized regulator of transcription (Levine, 1997; Zhao et al., 2000) . Many p53 target genes have been identi®ed and some are pro-apoptotic Bcl-2 family members (bax, noxa, and puma) (Miyashita and Reed, 1995; Nakano and Vousden, 2001; Oda et al., 2000; Yu et al., 2001) , still others are pro-apoptotic by means that have yet to be de®ned. Although the activity of p53 is not always related to transcription regulation, the ability of p53 to induce apoptosis in BRK cells in response to E1A expression requires that p53 be transcriptionally functional (Sabbatini et al., 1995b) . In this case, p53 must either activate the transcription of pro-apoptotic genes and/or repress the transcription of survival genes as an essential aspect of apoptosis induction. Although bax is induced by p53 in transformed BRK cells, bax induction is not sucient for apoptosis (Sakamuro et al., 1997) . E1A also fails to transform primary BMK cells de®cient for both Bax and Bak, although E1A can transform p53 de®cient cells, suggesting that p53 induces multiple pathways to implement cell death (Figure 3 ) (Degenhardt et al., in preparation).
The E1A plus temperature sensitive p53 mutant transformed BRK cells allow conditional expression of wild-type p53 and a detailed dissection of the p53 signaling events leading to cell death. As described for TNF-a-mediated apoptosis, p53 also induces a conformational change in the Bax amino-terminus, BaxBak interaction, cytochrome c and Smac/DIABLO release from mitochondria, caspase-9 and -3 activation, cleavage of various substrates, and DNA fragmentation and cell death (Figure 3 ) (Debbas and White, 1993; Han et al., 1996 Han et al., , 1998 Henry et al., 2001) . One interesting dierence is that caspase-8 is not activated by p53, nor is Bid cleaved to tBid (Henry et al., 2001) . Therefore, the p53-dependent conformational change in Bax must occur by a tBid-independent mechanism. Bid de®cient mice are not tumor prone (Yin et al., 1999) , and they would be expected to be if Bid played an essential role in p53-dependent apoptosis. Presumably, p53 stimulates an activity functionally similar to tBid, which can activate Bax and Bak to promote mitochondrial cytochrome c and Smac/DIABLO release. Abrogation of caspase function either genetically or pharmacologically rescues p53-dependent apoptosis indicating that caspase activity is required for cell death (Lowe et al., 1994; Sabbatini et al., 1997) . Whether p53 signals cell death exclusively through the mitochondria, or additionally signals a mitochondrial-independent death signaling pathway, remains to be determined.
Despite the gaps in our knowledge regarding implementation of p53-dependent apoptosis, it is clear that anti-apoptotic Bcl-2 family members completely block apoptosis by p53 (Chiou et al., 1994; D'SaEipper et al., 1996; Sabbatini et al., 1995a) . Thus, by whatever means p53 utilizes to induce cell death, it is capable of being inhibited by E1B 19K, Bcl-2, and other anti-apoptotic Bcl-2 family members. E1B 19K does not block the amino-terminal conformational change in Bax, but does bind Bax and Bak and inhibit Bax-Bak binding and the release of cytochrome c and Smac/DIABLO from mitochondria ( Figure 3) (Henry et al., 2001) . Although it is not clear yet if Bax and Bak oligomerize and whether E1B 19K inhibits their oligomerization, activation of caspase-9 and -3 downstream of mitochondria is inhibited by E1B 19K expression (Henry et al., 2001) . Thus, all of the mitochondrial signaling events leading to apoptosis are abrogated by E1B 19K expression (Henry et al., 2001 ). It will be of interest to determine if E1B 19K, Bcl-2, and Bcl-x L must also bind to other proapoptotic Bcl-2 family members induced by p53, and if this activity is required for complete inhibition of p53-dependent cell death.
The ability of E1B 19K to block p53-dependent apoptosis is sustained for long periods of time (weeks) which supports the notion that upregulation of an antiapoptotic Bcl-2-like activity in human tumors may be sucient to overcome the requirement for direct inactivation of p53 (Chiou et al., 1994; Sabbatini et al., 1995a) . In an interesting twist, the block to cytochrome c and Smac/DIABLO release from mitochondria by E1B 19K is incomplete, but nonetheless sucient to prevent caspase activation. Induction of wild-type p53 causes the rapid and synchronous release of both cytochrome c and Smac/DIABLO from mitochondria, whereas E1B 19K expression greatly delays the release of cytochrome c, and Smac/DIABLO (Henry et al., 2001) . This delayed release of cytochrome c and Smac/DIABLO is insucient to promote caspase-9 and -3 activation and both cytochrome c and Smac/DIABLO to become degraded in the cytoplasm. By 10 ± 14 days of p53-mediated death signaling, cytochrome c and Smac/DIABLO levels are substantially reduced in E1B 19K expressing cells that are completely viable (Henry et al., 2001) . This suggests that the disruption of the normal release of mitochondrial components observed in this case is nonproductive, which causes cytochrome c and Smac/ DIABLO to become degraded. A requirement for a synchronous and robust release of caspase activators from mitochondria may be a safeguard mechanism to prevent apoptosis in the presence of limited mitochondria damage. As cytochrome c de®cient cells are more resistant to apoptosis than wild-type cells , this suggests that either asynchronous or Figure 3 Regulation of p53-dependent apoptosis by E1A and E1B 19K in transformation gradual cytochrome c and Smac/DIABLO release from mitochondria may be a means to deplete cells of mitochondrial caspase activators and confer resistance to apoptosis. Indeed, these E1B 19K expressing cells depleted for cytochrome c and Smac/DIABLO are more resistant to apoptosis than control cells where the mitochondrial death checkpoint is intact (Henry et al., 2001) . Thus, even incomplete blockade of the mitochondrial death signaling pathway may be sucient to inhibit apoptosis. Interestingly, tumor cells are often found to have defects in mitochondrial respiration, which causes a shift to glycolytic metabolism (Dang et al., 1997) . Disruption of mitochondrial function instigated by the stimulation of apoptosis and the release of cytochrome c, but the failure to die, may explain this phenomenon.
Requirement for Bax and Bak in the regulation of apoptosis by E1A and E1B during viral infection
Infection of human cells with adenoviruses with loss-offunction mutations in the E1B 19K gene results in the degradation of host cell and viral DNA, enhanced cytopathic eects, large plaques, and premature death of the host cell (Figure 4) (White, 1994) . These phenotypes result from the expression of the E1A gene, which causes the induction of apoptosis, which can be deleterious to virus production (White et al., 1991) . The E1B 19K gene product normally inhibits apoptosis to permit virus replication without DNA fragmentation, and sustains cell viability to allow the virus life cycle to go to completion. Regulation of apoptosis by adenovirus E1A and E1B 19K provided the conceptual leaps relating the functional relationship between oncogenes and tumor suppressor genes and the control of cell viability. Moreover, it provided an important paradigm relating virus-host cell interaction and virus replication, to regulation of apoptosis. Insights from the analysis of apoptosis regulation during productive virus infection were derived from studies of both how E1A elicited the apoptotic response, and how apoptosis was inhibited by E1B 19K.
The ability of E1A to induce apoptosis during virus infection maps to both the Rb and p300 binding activities and cosegregates with the E1A transforming function White et al., 1991) . Rb de®cient mice die in embryogenesis in part due to deregulation of cell cycle progression and induction of cell death by apoptosis (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992) . Rb would normally inhibit E2F from driving cells into S phase, and inappropriate, deregulated E2F expression also stimulates DNA synthesis and p53-dependent apoptosis (Morgenbesser et al., 1994; Wu and Levine, 1994) . Binding and inhibition of p300 by E1A has more pleiotropic eects, but triggers p53 accumulation and apoptosis . In productive virus infection, however, p53 function is eectively disabled by E1B 55K-E4orf6 complex formation with p53, which targets p53 for degradation in proteasomes (Querido et al., 1997a; Steegenga et al., 1998) . Thus, in stark contrast to the transformation setting, the E1A-mediated apoptosis induced in virus infected human cells is completely independent of p53 function.
The exact signal to activate apoptosis upon E1A binding to Rb and p300 remains to be determined, but may be related to inappropriate cell cycle progression. Whatever this apoptotic signal is, it produces a conformational change in the Bax amino-terminus, Bax-Bak interaction, cytochrome c and Smac/DIABLO release from mitochondria, and the activation of caspase-9 and -3 (Figure 4) Wei et al., 2001) . Cleavage of PARP, lamins, ICAD, and other substrates contributes to cell death and the premature release of virus particles from infected cells (Chiou and White, 1998) . Unlike TNF-a-mediated apoptosis, the conformational change in Bax occurs by a caspase-8-and Bid-independent mechanism since neither are cleaved to their active forms during virus infection (Cuconati et al., submitted).
E1B 19K inhibits apoptosis in virus-infected cells largely by binding to Bak and preventing Bax-Bak interaction, Bax and Bak oligomerization, the release of cytochrome c and Smac/DIABLO from mitochondria, thereby blocking caspase-9 and -3 activation (Figure 4 ) (Cuconati et al., submitted; . Direct inhibition of mitochondrial death signaling by Bax and Bak is apparently a common mechanism by which the E1B 19K protein functions as an apoptotic inhibitor. Preventing caspase activation enables virus infection to be sustained in the absence of cell death.
Evaluation of the functional role of speci®c caspase substrates in apoptosis has provided insight into their individual role in the dismantling of the cell that adenovirus wishes to avoid. By blocking caspase-3 activation, E1B 19K prevents cleavage of ICAD during infection and the apoptotic nuclease CAD is not activated to degrade viral and cellular DNA (Degenhardt et al., in preparation). E1B 19K also prevents caspase-3 activation by TNF-a during virus infection, which prevents CAD activation and viral and cellular DNA fragmentation (Degenhardt et al., in preparation) . Preventing the degradation of the viral genome during productive infection, triggered by either E1A or cytokines such as TNF-a, likely contributes to the eciency of virus production. Lamins, which maintain the structural integrity and organization of the nuclear envelope are also cleaved by caspases (Cryns and Yuan, 1998) . Preventing lamin cleavage speci®cally using caspase-resistant, dominant-negative lamin mutants delays both the destruction of the nucleus and cell death Oncogene Apoptosis regulation by E1A and E1B E White . E1B 19K likewise prevents lamin cleavage during infection by blocking caspase activation signals from the mitochondria (Rao et al., 1997) , and since adenovirus replicates in the nucleus, preserving nuclear integrity may be advantageous to the virus.
Regulation of apoptosis by viruses is now recognized as an essential and important aspect of the replicative life cycle of many viruses and an integral part of virushost interactions. These same mechanisms of apoptosis regulation are an essential component of oncogenic transformation by viruses and the interaction between infected cells and the immune system of the host. Adenovirus has provided a paradigm for unraveling these mechanisms that are likely common to many virus-host interactions. Other viruses besides adenoviruses have been found to encode Bcl-2 homologues (herpes viruses, African swine fever virus, and fowlpox virus) (Roulston et al., 1999) . IAPs were ®rst identi®ed as baculovirus encoded genes (Birnbaum et al., 1994) .
Herpes and poxviruses encode v-FLIPs (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) . Poxviruses also encode serpins that act as direct caspase inhibitors (Brooks et al., 1995; Komiyama et al., 1994) . All of these activities block killing of the infected cell by either the infection itself or the immune system, and can also subdue an in¯ammatory response to infection. These examples can provide model systems for de®ning the molecular events controlling cell viability.
